Brahm Goldstein
Overview
Explore the profile of Brahm Goldstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
80
Citations
2573
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mahlangu J, Mancuso M, Fischer K, Djambas Khayat C, Carvalho M, Karim F, et al.
Haemophilia
. 2025 Feb;
PMID: 39917944
Introduction: Clinical trials and real-world evidence have demonstrated the efficacy and safety of rVIII-SingleChain in previously treated patients with haemophilia A. Aim: To investigate the safety and efficacy of rVIII-SingleChain...
2.
Stephens S, Carroll-Ledbetter C, Duckert S, Coffman T, Nelson M, Rodgers J, et al.
J Trauma Acute Care Surg
. 2025 Jan;
98(3):492-499.
PMID: 39787574
Background: The interactive media-based approach to community consultation and public disclosure (CC/PD), a key step when conducting exception from informed consent (EFIC) clinical trials, is intended to be completed in...
3.
Stephens S, Carroll-Ledbetter C, Duckert S, Coffman T, Nelson M, Brown K, et al.
JAMA Surg
. 2024 Jul;
159(9):1051-1058.
PMID: 38959020
Importance: Exception From Informed Consent (EFIC) research requires community consultation (CC) and public disclosure (PD). Traditional methods of conducting CC and PD are slow, expensive, and labor intensive. Objective: To...
4.
Pipe S, Leebeek F, Recht M, Key N, Castaman G, Miesbach W, et al.
N Engl J Med
. 2023 Feb;
388(8):706-718.
PMID: 36812434
Background: Moderate-to-severe hemophilia B is treated with lifelong, continuous coagulation factor IX replacement to prevent bleeding. Gene therapy for hemophilia B aims to establish sustained factor IX activity, thereby protecting...
5.
Hood C, Goldstein J, Milling T, Refaai M, Bajcic P, Goldstein B, et al.
Blood Adv
. 2022 Dec;
7(10):2206-2213.
PMID: 36574241
Restoration of the international normalized ratio (INR) to values <1.5 is commonly targeted to achieve hemostasis in patients with major bleeding or undergoing urgent surgery who are treated using vitamin...
6.
Go A, Leong T, Sung S, Wei R, Harrison T, Gupta N, et al.
J Thromb Thrombolysis
. 2022 Aug;
54(3):470-479.
PMID: 35984591
Limited data exist in large, representative populations about whether the risk of thromboembolic events varies after receiving four-factor human prothrombin complex concentrate (4F-PCC) versus treatment with human plasma for urgent...
7.
Mahlangu J, Karim F, Stasyshyn O, Korczowski B, Salazar B, Lucas S, et al.
Res Pract Thromb Haemost
. 2022 Feb;
6(2):e12665.
PMID: 35224416
Background: rVIII-SingleChain is a recombinant single-chain factor VIII used to treat people with hemophilia A. Objectives: The aim of this extension study was to investigate the long-term safety and efficacy...
8.
Tiede A, Allen G, Bauer A, Chowdary P, Collins P, Goldstein B, et al.
Haemophilia
. 2019 Nov;
26(1):47-55.
PMID: 31778283
Introduction: SHP656 is the first factor VIII (FVIII) product developed using polysialylation (PSA) technology, in which full-length recombinant (r) FVIII (anti-haemophilic factor [recombinant]) is conjugated with a 20 kDa PSA...
9.
Goldstein B, Randolph A
Pediatr Crit Care Med
. 2014 Feb;
15(2):183.
PMID: 24492192
No abstract available.
10.